Nabriva Therapeutics AG

Nabriva Therapeutics — Conference Presentation (September 2017)

28 slides from Nabriva Therapeutics's conference presentation, Sep 18, 2017

  1. Slide 1: Forward-looking statements

    Any statements in this presentation about future expectations, plans and prospects for Nabriva, including but not limited to statements about the development of Nabriva’s product candidates, such as plans for the design, conduct and timelines of Nabriva’s ongoing Phase 3 clinical trial of lefamulin

  2. Slide 2: 2017 - A Transformational Year for Nabriva

    Significant medical need for a new treatment of CABP due to increasing bacterial resistance and high morbidity and mortality Lefamulin in two global, pivotal Phase 3 trials for moderate-to-severe CABP with topline data received in September 2017 and expected for LEAP 2 in the spring of 2018 Investin

  3. Slide 3: Pneumonia: A Leading Cause of Morbidity, Mortality and Cost

    Pneumonia: A Leading Cause of Morbidity, Mortality and Cost 5-6MM Approximately CABP cases annually Mortality rate for admitted patients Mortality rate for those who require admission to ICU Leading cause of death ~15% ~25 - 30% ~8th Sources: File TM.J Manag Care Pharm.2009;15(2 Suppl):S5-S11 - Fing

  4. Slide 4: Pleuromutilins Represent a New Class of Antibiotics for Systemic Human Use

    Lefamulin A site P site PTC of the 23S rRNA of the large ribosomal subunit Pleuromutilins Represent a New Class of Antibiotics for Systemic Human Use Lefamulin: Discovered and developed by Nabriva Therapeutics Novel mechanism of action with four distinctive binding sites in highly conserved core of

  5. Slide 5: LEAP Trial Design and Demographics

    LEAP 1 Trial Design and Demographics

  6. Slide 6: LEAP Phase 3 Trial Design

    LEAP 1 Phase 3 Trial Design IV Initiation with Option for Switch to Oral Administration Lefamulin (± Placebo) Moxifloxacin (± Linezolid) Informed Consent & Baseline Assessments Randomization Early Clinical Response Assessment (96 +/- 24 hrs After 1st Dose) End of Treatment Within 2 Days After Last D

  7. Slide 7: LEAP Phase 3 Trial Design: FDA and EMA Primary Endpoints

    LEAP 1 Phase 3 Trial Design FDA and EMA Primary Endpoints At 72 to 120 hours after first dose of study drug: Improvement in > 2 of 4 CABP signs/symptoms No worsening in any CABP signs/symptoms Alive Did not receive non-study antibacterial therapy for the treatment of CABP Non-inferiority margin 12.5

  8. Slide 8: LEAP Phase 3 Trial Design: Symptom Assessment for ECR

    LEAP 1 Phase 3 Trial Design Symptom Assessment for ECR Symptom Absent (0) Mild (1) Moderate (2) Severe (3) Dyspnea Resolution (to pre-CABP baseline) or absence of dyspnea Dyspnea on exertion (e.g., climbing stairs) Dyspnea with normal/routine activities (e.g., walking) Dyspnea at rest or requiring o

  9. Slide 9: LEAP Phase 3 Trial Populations and Disposition

    LEAP 1 Phase 3 Trial Populations and Disposition High Patient Completion and Microbiological Isolate Recovery Rates Category Lefamulin Moxifloxacin (±linezolid) TOTAL All Randomized 276 275 551 Modified ITT (mITT) 273 (98.9%) 273 (99.3%) 546 (99.1%) Clinically Evaluable-Test of Cure (CE-TOC) 236 (85

  10. Slide 10: LEAP 1 Phase 3 Trial ITT Population: Balanced Demographics

    Category Lefamulin Moxifloxacin (±linezolid) TOTAL Age (Years; Mean) 61.0 59.6 60.3 <65 years 144 (52.2%) 167 (60.7%) 311 (56.4%) 65-74 74 (26.8%) 66 (24.0%) 140 (25.4%) >75 58 (21.0%) 42 (15.3%) 100 (18.1%) Gender Male 170 (61.6%) 160 (58.2%) 330 (59.9%) BMI (kg/m2) (Mean) 26.48 26.33 26.40 Race (W

  11. Slide 11: LEAP Trial Efficacy Results

    LEAP 1 Trial Efficacy Results

  12. Slide 12: Lefamulin Meets FDA Primary Endpoint of ECR

    High Response Rates in Both Arms LEAP 1 Trial Efficacy Results Lefamulin Meets FDA Primary Endpoint of ECR Percent Responders Delta (95% CI) -2.9 (-8.5, 2.8) 0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100% ECR 87.3% 90.2% Lefamulin Moxifloxacin (±linezolid)

  13. Slide 13: Lefamulin Meets EMA Primary Endpoints

    EMA Primary Endpoints: IACR in CE and mITT at TOC LEAP 1 Trial Efficacy Results Lefamulin Meets EMA Primary Endpoints Percent Responders Delta (95% CI) -2.5 (-8.4, 3.4) Delta (95% CI) -2.6 (-8.9, 3.9) 0% 20% 40% 60% 80% 100% IACR CE - TOC IACR mITT 86.9% 81.7% 89.4% 84.2% Lefamulin Moxifloxacin (±li

  14. Slide 14: ECR by PORT Risk Classification: ITT Population

    ECR by PORT Risk Classification: ITT Population Lefamulin Demonstrated High Response Rates Across All Severities of CABP PORT Class Lefamulin Moxifloxacin (±linezolid) Treatment Difference (95% CI) II 0 1/1 (100%) -- III 175/196 (89.3%) 187/201 (93.0%) -3.7 (-9.8, 2.3) IV 63/76 (82.9%) 57/70 (81.4%)

  15. Slide 15: ECR by Baseline Pathogen: Typical Pathogens

    ECR by Baseline Pathogen – Typical Pathogens [micro ITT] Lefamulin Demonstrated High Response Rate Across All of the Most Common Causes of CABP Lefamulin Moxifloxacin (±linezolid) Microbiological ITT (microITT) N = 160 (58.0%) N = 159 (57.8%) Baseline Pathogen ECR (%) ECR (%) Gram Positive S. pneumo

  16. Slide 16: ECR by Baseline Pathogen: Typical and Atypical Pathogens

    ECR by Baseline Pathogen – Typical and Atypical Pathogens [micro ITT] High Response Rate Seen Across All of the Most Common Causes of CABP Lefamulin Moxifloxacin (±linezolid) Baseline Pathogen ECR (%) ECR (%) Gram Negative H. influenzae 8/8 100% 6/7 85.7% M. catarrhalis 47/52 90.4% 52/55 94.5% Atypi

  17. Slide 17: LEAP Trial Safety and Tolerability Data

    LEAP 1 Trial Safety and Tolerability Data

  18. Slide 18: Overview of Adverse Events

    Overview of Adverse Events Low Rates of Discontinuation Observed Patients with at Least One Lefamulin (n=273) Moxifloxacin (±linezolid) (n=273) Adverse Events (AE) 105 (38.5%) 105 (38.5%) Treatment Emergent AE (TEAE) 104 (38.1%) 103 (37.7%) Serious AE (SAE) 19 (7.0%) 13 (4.8%) Related AE 41 (15.0%)

  19. Slide 19: Treatment Emergent Adverse Events of Interest

    Treatment Emergent Adverse Events of Interest TEAEs in 6.6% and 13.0% of subjects receiving lefamulin and moxifloxacin (±linezolid), respectively No cases of Clostridium difficile infection were reported in either treatment group Diarrhea was observed in 0.7% and 7.7% of subjects receiving lefamulin

  20. Slide 20: TEAEs > 2% for Study Medication: Safety Population

    TEAEs > 2% for Study Medication: Safety Population Lefamulin was Well Tolerated with a Lower Incidence of Diarrhea Preferred Term Lefamulin (n=273) Moxifloxacin (±linezolid) (n=273) Hypokalemia 8 (2.9%) 6 (2.2%) Nausea 8 (2.9%) 6 (2.2%) Insomnia 8 (2.9%) 5 (1.8%) Infusion Site Pain 8 (2.9%) 0 (0.0%)

  21. Slide 21: Maximum Post Baseline Liver Enzymes: Safety Population

    Maximum Post Baseline Liver Enzymes: Safety Population Low Incidence of Elevated Liver Function Tests Lab Parameter Lefamulin Moxifloxacin (±linezolid) Any Post Baseline ALT >3xULN 19/268 (7.1%) 17/267 (6.4%) >5xULN 6/268 (2.2%) 5/267 (1.9%) >10xULN 1/268 (0.4%) 0/267 (0.0%) Any Post Baseline AST >3

  22. Slide 22: Maximum Post Dose QTcF Changes (Day 3)

    Maximum Post Dose QTcF Changes (Day 3) Parameter Lefamulin Moxifloxacin (±linezolid) Post Dose Increase 30 - 60 msec 12 (4.6%) 14 (5.4%) Post Dose Increase > 60 msec 0 (0.0%) 1 (0.4%) Post Dose Value > 500 msec 1 (0.4%) 1 (0.4%)

  23. Slide 23: LEAP 1 Phase 3 Clinical Trial Highlights

    LEAP 1 Phase 3 Clinical Trial Highlights Lefamulin is the first anti-bacterial agent of a new class of antibiotics with favorable Phase 3 data in CABP in more than 15 years Lefamulin’s efficacy data - in our first trial treating adults with CABP - was comparable to a gold standard therapy Lefamulin

  24. Slide 24: Acknowledgments

    Acknowledgments Patients and families Clinical investigators and their staff Collaborating research organizations We are grateful for the participation and contributions of the following in the LEAP 1 trial: Thomas File, M.D. George Talbot, M.D. Anita Das, Ph. D. The Nabriva Therapeutics team

  25. Slide 25: Lefamulin Addresses Factors Influencing CABP Treatment Choices

    Lefamulin Addresses the Factors that Increasingly Influence Treatment Choices for CABP *10 days in clinical trials for confirmed MRSA CABP patients 5-7 days IV/PO Monotherapy for Most* Patients Novel Mechanism of Action CABP Targeted Spectrum of Activity Stewardship Guidelines recommend use of targe

  26. Slide 26: Anticipated Lefamulin Milestones

    Feb 2017 Blinded, interim analysis to confirm LEAP 1 sample size Sept 2017 Topline data from LEAP 1 Phase 3 trial for CABP Anticipated Lefamulin Milestones Spring 2018 Topline data from LEAP 2 Phase 3 trial for CABP 2H 2018 Regulatory filing in US (priority review request to FDA) for CABP

  27. Slide 27: Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results

    Lefamulin Evaluation Against Pneumonia (LEAP 1) Phase 3 Topline Results September 18, 2017

  28. Slide 28: Nabriva

    nabriva Lefamulin Evaluation Against Pheumg (LEAP 1) Phase 3 Topline Results September 18, 2017

Nabriva Therapeutics — Conference Presentation (September 2017) on 6ix